Targeted lipid nanoparticles
In one sentence
Targeted lipid nanoparticles use formulation or surface features to favor delivery to particular tissues or cells, but enrichment must be distinguished from selective functional expression.
The intuition
Putting an address on a parcel helps it reach a destination, but does not prove that every parcel reaches the right person or that its contents are used. Lipid nanoparticles (LNPs) need more than an address: they must survive the journey, enter cells and release useful cargo. The analogy also misses competition from other tissues that can take up particles.
Before you start: LNPs introduce the carrier; DNA → RNA → protein explains expression.
How it works
One strategy attaches a ligand, a binding molecule such as an antibody fragment, to the particle surface. The ligand recognizes a molecule on the intended cell. Another strategy changes lipid composition to favor delivery to an organ. These strategies can overlap, but “more delivery to the lung” and “selective engineering of a T-cell subset” are different claims.
Biodistribution describes where administered material goes. Functional delivery asks whether its cargo reaches a usable location and performs its intended job. Messenger RNA (mRNA) must reach the cytoplasm to be translated. Material trapped inside an endosome, a cellular uptake compartment, may be detectable without producing enough protein.
An organ signal cannot substitute for a cell-specific expression measurement.
Primary studies have demonstrated organ-enriched delivery by changing particle composition, and receptor-guided delivery of chimeric antigen receptor (CAR)-encoding RNA to T cells. Those are results in specified systems. Cell-marker expression, cell state, species, route and dose can all affect performance. A ligand binding its marker in a dish is insufficient evidence of selective delivery throughout a patient.
Why it matters in cancer
An LNP can carry instructions to an immune cell that will later recognize a tumor. The delivery target and the tumor target can be entirely different. For a vaccine, the intended recipient may instead be an antigen-presenting cell. Ask which cell must make which protein, and how that was measured.
The payload also matters. Ordinary CAR-encoding mRNA generally provides transient receptor expression. RNA encoding a genome editor can cause lasting DNA changes. A temporary RNA molecule does not guarantee a temporary biological intervention.
Try it
A fictional particle carries a fluorescent lipid and a receptor-encoding RNA. Whole-lung fluorescence rises, but the report does not identify expressing cells. Has it shown selective T-cell engineering?
Answer: No. It shows distribution of the label. The team needs identified-cell measurements of useful cargo delivery and receptor expression, including unintended cell populations.
Common confusions
- Targeted versus exclusive: Favoring a population is not proof of zero off-target delivery.
- Organ targeting versus cell targeting: An organ contains many cell types.
- Particle uptake versus endosomal escape: Entry into a compartment is not successful RNA use.
- Delivery specificity versus clinical safety: The expressed protein and downstream immune response have their own risks.
Related concepts
- Delivery targeting versus cancer targeting.
- CAR anatomy explains what an engineered immune cell makes.
Sources and scope
Source check: October 9, 2026; expert and learner review pending. These are primary preclinical studies, not proof of human solid-tumor efficacy.
- Cheng et al., 2020: selective organ targeting by LNP composition.
- Rurik et al., 2022: targeted RNA delivery to generate CAR T cells in a mouse cardiac-injury model.
- Hunter et al., 2025: targeted LNP engineering in human-cell experiments and animal models.